Clarity begins subject dosing in prostate cancer therapy trial

Clarity begins subject dosing in prostate cancer therapy trial

Submitted by admin on October 10, 2022 - 10:55am
Source: 
Clinical Trials Arena
News Tags: 
Clarity Pharmaceuticals
prostate cancer
clinical trials
Headline: 
Clarity begins subject dosing in prostate cancer therapy trial
snippet: 

Clarity Pharmaceuticals has dosed the first participant in the therapeutic phase of its Phase I/II theranostic trial of 64Cu/67Cu SAR-bisPSMA theranostic products for metastatic, castrate-resistant prostate cancer (mCRPC) treatment.

Do Not Allow Advertisers to Use My Personal information